제품 수집
제품 세부정보
- ProductSizeAmountActiveMax® Human 4-1BB Ligand / TNFSF9 (71-254) μBeads, premium grade (for cells)2.5 mg2.5×10⁷ beadsActiveMax® Human 4-1BB Ligand / TNFSF9 (71-254) μBeads, premium grade (for cells)10 mg (2.5 mg×4)1×10⁸ beads
Product Show
This product can be directly isolated using conventional column-free magnetic stand (eg. Cat. MB-01/ MB-02/ MB-03/ MB-04). Please note that due to its micron-scale size, it is not compatible with commercially available column-based (M/D/L) magnetic separation systems.
Product Description
ActiveMax® Human 4-1BB Ligand / TNFSF9 (71-254) μBeads, premium grade (for cells) are uniform, superparamagnetic beads of 5.5 µm in diameter immobilized with Human 4-1BB Ligand / TNFSF9 (71-254) Protein, expressed from human 293 cells (HEK293) and contains AA Arg 71 - Glu 254 (Accession # P41273-1 ).
ActiveMax® Human 4-1BB Ligand / TNFSF9 (71-254) μBeads, premium grade (for cells) are produced under sterile manufacturing conditions (ISO 5) , and no animal- or human-derived components are used throughout the production process. It is produced under our rigorous quality control system that includes a comprehensive set of tests including sterility and endotoxin tests.Application
ActiveMax® Human 4-1BB Ligand / TNFSF9 (71-254) μBeads, premium grade (for cells) are designed to stimulate in vitro 4-1BB Ligand / TNFSF9 (71-254)-specific CAR-T cells or UCAR-T cells, similar to the tumor cell lines that express human 4-1BB Ligand / TNFSF9 (71-254) antigen. It can be used as follows:
Evaluating the characteristics of CAR-T cells or UCAR-T cells.
In vitro expansion of 4-1BB Ligand / TNFSF9 (71-254)-specific CAR-T cells or UCAR-T cells.
In vitro enrichment of 4-1BB Ligand / TNFSF9 (71-254)-specific CAR-T cells or UCAR-T cells.Reconstitution
See Certificate of Analysis (CoA) for detailed instruction.
Storage
This product is stable in storage under the following conditions: -20˚C for 12 months in lyophilized state. -70°C for 3 months under sterile conditions after reconstitution.
Please protect from light and avoid repeated freeze-thaw cycles. Immediate use after reconstitution is highly recommended.
Sterility
Negative
Endotoxin
Less than 0.002 EU per μg by the LAL method / rFC method.
Mycoplasma
Negative
Important Note
This product is for research use only and not intended for therapeutic or in vivo diagnostic use.
Formulation
Lyophilized in PBS with 0.1% HSA，pH 7.4. Trehalose is added as protectant before lyophilization.
ACRO Quality Management System
고객님도 확인한 상품
데이터 표시
FACS Data
Assay of human 4-1BB Ligand / TNFSF9 (71-254) protein on the μBeads surface by Flow cytometry. The human 4-1BB Ligand / TNFSF9 (71-254) protein conjugated on the μBeads (Cat. No. MBS-C012) surface were fluorescently stained using PE anti-human CD137L (4-1BB Ligand) Antibody and analyzed by flow cytometry.
Protocol
사용자 리뷰 댓글 남기기
FAQ
- product
Can lyophilized proteins remain stable during room-temperature shipping or temporary room-temperature exposure?
In general, lyophilized proteins remain stable during room-temperature shipping or temporary exposure to room-temperature conditions.
Many ACROBiosystems recombinant proteins are supplied in lyophilized (freeze-dried) form. The lyophilization process effectively removes moisture from the product, helping reduce degradation-related reactions and improve protein stability during transportation and storage.
To evaluate the stability of lyophilized proteins under normal temperature conditions, ACROBiosystems conducted a stability study on 11 representative lyophilized protein products at 37°C. The study demonstrated that these proteins maintained good quality stability after storage at 37°C for approximately 20 days. Based on these validation results, temporary room-temperature exposure during shipping or handling is generally not expected to have a significant impact on product quality or downstream application performance.
To ensure optimal long-term stability, products should be stored according to the storage conditions specified in the product Certificate of Analysis (COA) upon receipt.
Supporting Document
프론티어 진행
의약품 개발 진행- 영어 이름：
Tumor necrosis factor ligand superfamily member 9
- 카테고리：
- 상장 의약품 수：
0 상세
- 임상 의약품 수：
2 상세
- 최고 개발 단계：
Phase 2 Clinical
연락하기
전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521
신약 후보물질 라이선싱